BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Siena Biotech S.p.A. Selects the QUMAS Biotechnology Package as Its Regulatory Content Management Solution


1/5/2010 10:48:44 AM

JERSEY CITY, NJ--(Marketwire - January 05, 2010) -

QUMAS, the leading provider of Compliance Solutions to highly regulated companies, today announced that Siena Biotech SpA has selected the QUMAS Biotechnology Package (based on the industry leading eDMS DocCompliance) to improve document control, reduce approval lifecycles of documents and SOPs, and to become eCTD ready. Siena Biotech SpA has also selected QUMAS ProcessCompliance to automate Change Control and Non-Conformance Management and drive efficiencies across both processes. Initially, Siena Biotech SpA will roll the QUMAS applications out to 30 users.

"With this Package, Siena Biotech SpA is gaining access to a world class document management solution, packaged to ensure low acquisition and implementation costs for biotechnology companies," said Ken Hayward, CTO at QUMAS. "By harnessing the power of DocCompliance with pre-configured industry practices for R&D leading to eCTD readiness, Siena Biotech SpA will be up and running with this solution very quickly."

Siena Biotech chose the QUMAS Solutions because of the built in best practices for biotechnology operations, which suited its IT department that did not have the bandwidth to spend months configuring systems. The QUMAS Quickstart approach means that the organization will be up and running in a short time frame, with a relatively low cost. According to Siena Biotech, the look and feel of the interface is great, and very user-friendly.

Goran Westerberg, head of Development Operations in Siena Biotech SpA commented: "We were in the market for a flexible and up-to-date system for document management and found QUMAS Solutions to be the ideal fit for our organization, allowing the system to grow with the portfolio of the Company."

Federico Paoli, Siena Biotech's head of IT, concluded that "QUMAS was able to quickly map our needs and provide a solution that fits our infrastructure."

H@rlock, the QUMAS partner in Italy, has been instrumental in engaging Siena Biotech with QUMAS, in providing local representation and continue to represent QUMAS throughout the Italian market.

This announcement marks the beginning of a new area of business for QUMAS, extending its traditional tier one and two life sciences focus further across the sector to smaller organizations that require the same solutions, but at a lower cost and in an easy to implement format.

About QUMAS: QUMAS is the leader in Enterprise Regulatory Compliance Solutions with more than 250 global customer deployments and over 15 years of experience helping companies in highly regulated industries. For more information visit www.qumas.com

About Siena Biotech: Siena Biotech SpA is an innovative drug discovery company focused primarily on degenerative and proliferative diseases of the central nervous system with the aim of discovering new drugs for therapeutic intervention.

The company was established in 2000 by the Monte dei Paschi di Siena (MPS) Foundation, which is a non-profit, private institution. Since its inception, the company has grown rapidly to achieve the critical mass needed to compete successfully, and has developed a well-balanced and innovative project portfolio focused on the CNS diseases of Alzheimer's and Huntington's diseases and brain tumours. For more information visit www.sienabiotech.com


MEDIA CONTACT:

Caoimhe Kiely
Global Head of Marketing
QUMAS
+353 21 4915100
Email Contact
www.qumas.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES